Alexion was recently written up as one of the three best-run Biotechnology companies in the USA .
"Alexion's focus on ultra-rare diseases has led to ultra-rare results.
The biotech achieved a 15.1% ROIC over the past year. Its five-year
average of 21.6% is even better.
Earnings growth has been stellar. Alexion's net income over a
trailing 12-month window increased 49% during the last year. Over the
past five years, Alexion saw earnings skyrocket by more than 460%.
The company's CEO, Dr. Leonard Bell, helped develop Soliris, which
treats the rare diseases paroxysmal nocturnal hemoglobinuria and
atypical hemolytic uremic syndrome. Bell co-founded Alexion in 1992 and
led the company through its IPO four years later. He also was
instrumental in Alexion gaining regulatory approval for Soliris and
successfully launching the drug. Along the way, Alexion has received
several honors, including being named the world's second-most innovative
company by Forbes in 2012. "
No comments:
Post a Comment